This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AVEO AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AVEO Pharmaceuticals Stock (NASDAQ:AVEO) 30 days 90 days 365 days Advanced Chart Get AVEO Pharmaceuticals alerts:Sign Up Key Stats Today's Range$14.99▼$15.0050-Day Range$14.90▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More… Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVEO Stock News HeadlinesWe have a winner: Brookfield grants exclusivity for $3b AveoApril 12, 2025 | afr.comBAFO alert: One more round for Scape, GIC in $3b Aveo saleApril 3, 2025 | afr.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 27, 2025 | Crypto Swap Profits (Ad)Big Pharma faces heat as India records 307 drug pricing violationsMarch 25, 2025 | msn.comCDSCO eases rules, pharma firms can now get 1-year NoC online via Sugam portalMarch 9, 2025 | msn.comThe Indian company filling West Africa with fake drugsMarch 5, 2025 | msn.comNAFDAC blacklists Indian firm for importing hard drugsMarch 1, 2025 | msn.comNAFDAC blacklists Indian firm for importing hard drugsMarch 1, 2025 | msn.comSee More Headlines AVEO Stock Analysis - Frequently Asked Questions How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company earned $15.17 million during the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. When did AVEO Pharmaceuticals' stock split? AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Alibaba Group (BABA), Meta Platforms (META), Exelixis (EXEL) and NVIDIA (NVDA). Company Calendar Last Earnings11/08/2021Today4/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AVEO CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AVEO) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVEO Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.